mystartupXX Alum Cypher Genomics Leads in Genomic Innovation
Rady School and mystartupXX alum Ashley Van Zeeland’s (MBA ’12) startup, Cypher Genomics, is quickly establishing itself as a leader in genomic innovation both in San Diego region and beyond.
Cypher Genomics was recently named one of the San Diego Venture Group’s 31 COOL Companies of 2015 and was featured as one of the 12 San Diego Tech Startups to Watch in 2016 by Xconomy. Cypher Genomics also received the MetroConnect Prize from San Diego Regional Economic Development Corporation’s Go Global San Diego Initiative.
“When you start out as an entrepreneur, all you have is a vision of how the products you will build can have an impact. It's wonderful to be at the point now where the technology that we have developed is being recognized both locally and abroad for that impact!” said Van Zeeland.
Prizes from these awards include a spot to exhibit at Xconomy’s annual summit in front of 40 representatives from prestigious venture capital firms and $10,000 in matching funds through MetroConnect to assist in expanding the company to foreign markets including the United Kingdom, Japan and China.
Cypher Genomics provides automated genome interpretation for clinical labs and pharmaceutical companies to improve the effectiveness and efficiency of both molecular diagnostic tests and drug discovery. The company grew out of a technology that Van Zeeland developed during her time at the Scripps Translational Institute. Van Zeeland used this idea during her Lab to Market capstone course series at the Rady School.
She was then accepted to the mystartupXX accelerator program, a collaboration of the California Institute for Innovation and Development, the Rady School of Management and the Jacobs School of Engineering which seeks to level the playing field for female entrepreneurs by providing mentors and access to funding and investors.
Cypher Genomics is also continuing collaborations with Sequenom, a leading molecular diagnostics company, UPenn/CurePSP, a research study aimed at finding genetic causes of progressive supranuclear palsy and Clinic for Special Children, which aims to diagnose rare diseases in children using automated genomic interpretation tools. Within these collaborations and recent recognition Cypher Genomics continues to enhance and improve diagnostics and prove itself as a leader in genomic advancement within the San Diego region and beyond.
“We still have a long way to go to fulfill our mission of revolutionizing healthcare through advanced genome interpretation, but with the great team and technology at Cypher Genomics I am looking forward to the next few years of continuing to build this business,” said Van Zeeland.